

Figure S1. Mechanisms underlying T-cell activation with potential differences in PD-1/PD-L1 tumour intrinsic signaling. T-cell activation is a two-step process that begins with TCR recognition of an antigen loaded on MHC localized on APC. Only TCR specific antigens induce further signaling. Tcell activation can only be completed by costimulatory - antigen independent - stimulus. Despite numerous T-cell co-activators, the interaction between CD80/86 molecules of APC and CD28 protein of the T-cell is considered as the most significant. TCR signaling triggers a cascade of downstream events mediated by ZAP70 phosphorylation, followed by LAT signalosome formation. It is essential for signal propagation to calcium-dependent pathway, the mitogen- activated protein kinase (MAPK) and to the nuclear factor κB (NF- κB) pathway. These pathways lead to the recruitment of transcription factors to chromatin and gene expression fundamental for T-cell proliferation, differentiation, motility or stress response. Alternatively, TCR signaling acts through PI3K activated by the co-stimulatory interaction between CD28 and CD80/86. PI3K signal transduction leads to AKT stimulation that is controlled by PTEN negative regulation. AKT activity facilitates mTOR signal propagation by either of its downstream effectors: S6RP or 4EBP1 as their activity is coupled with recruitment of ribosomes to mRNA and mRNAs translation. T-cell activation is negatively controlled by CTLA-4 and PD-1 immune-checkpoint activity. While CTLA-4 disrupts co-stimulatory signaling competing with CD28 for binding to CD80/86 molecule, PD-1 signaling negatively regulates activated T-cell function. Upon PD-1 engagement by PD-L1, SHP-2 is recruited to PD-1 cytoplasmic tail to further abrogate ZAP70 and ERK signaling as well as CD28 mediated activation of PI3K - a key mediator for complex AKT signaling. Consequently, mTOR pathway is no longer stimulated leading to impairment of cellular growth, proliferation and survival and ultimately to T-cell functional exhaustion. * The star symbol was used to emphasize mechanisms that may be differently regulated in PD-1/PD-L1 tumour intrinsic signaling and were extensively discussed in the main text of this review.